The median (interquartile range [IQR]) age of these patients was 60 (50-69) years, and the median (IQR) age varied by breast cancer subtype: 61 (51-70) years for women with HR-positive and ERBB2-negative subtype, 56 (47-66) years for women with HR-positive and ERBB2-positive subtype, 56 (48-65) years for women with HR-negative and ERBB2-positive subtype, and 57 (48-67) years for women with triple-negative breast cancer (TNBC) subtype. The gene discussed is ERBB2; the disease is breast carcinoma.